In another study, Galluzzi et al. [62] used RANK/RANK-L blockers in metastatic mammary tumors and observed that their use decreased the carcinogenesis of the tumors and consequently reduced the percentage of metastases in the study group. The gene discussed is TNFSF11; the disease is breast cancer.